{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T00:11:39Z","timestamp":1793059899703,"version":"4.5.0"},"reference-count":92,"publisher":"Radcliffe Medical Media Ltd","license":[{"start":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T00:00:00Z","timestamp":1620864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/legalcode"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur Cardiol"],"abstract":"<jats:p>Cardiovascular diseases and psoriasis have been well established as separate entities, however, there is uncertainty with regards to a link between the two diseases. A few environmental, psychological and social factors have been implicated as potential common risk factors that may exacerbate the two diseases, and an array of complex immune and non-immune inflammatory mediators can potentially explain a plausible link. Pharmacotherapy has also played a role in establishing a potential association, especially with the advent of biological agents which directly act on inflammatory factors shared by the two diseases. This review will look at existing evidence and ascertain a potential correlation between the two.<\/jats:p>","DOI":"10.15420\/ecr.2020.15.r2","type":"journal-article","created":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T12:46:14Z","timestamp":1620996374000},"source":"Crossref","is-referenced-by-count":24,"title":["The Association Between Psoriasis and Cardiovascular Diseases"],"prefix":"10.15420","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3608-6171","authenticated-orcid":false,"given":"Ahmed","family":"Zwain","sequence":"first","affiliation":[{"name":"North West Deanery, Aintree University Hospital, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1819-2747","authenticated-orcid":false,"given":"Mohanad","family":"Aldiwani","sequence":"additional","affiliation":[{"name":"East Midlands Deanery, University Hospitals of Leicester NHS Trust, Leicester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hussein","family":"Taqi","sequence":"additional","affiliation":[{"name":"East Midlands Deanery, Royal Derby Hospital, Derby, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6096","published-online":{"date-parts":[[2021,5,13]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet 2007;370:263\u201371. https:\/\/doi.org\/10.1016\/S0140-6736(07)61128-3; PMID:\u00a017658397.","DOI":"10.1016\/s0140-6736(07)61128-3"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Armstrong AW, Harskamp CT, Armstrong EJ. The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies. Nutr Diabetes 2012;2:e54. https:\/\/doi.org\/10.1038\/nutd.2012.26; PMID:\u00a023208415.","DOI":"10.1038\/nutd.2012.26"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Takeshita J, Wang S, Shin DB, et al. Effect of psoriasis severity on hypertension control: a population-based study in the United Kingdom. JAMA Dermatology 2015;151:161\u20139. https:\/\/doi.org\/10.1001\/jamadermatol.2014.2094; PMID:\u00a025322196.","DOI":"10.1001\/jamadermatol.2014.2094"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Binus AM, Han J, Qamar AA, et al. Associated comorbidities in psoriasis and inflammatory bowel disease. J Eur Acad Dermatol Venereol 2012;26:644\u201350. https:\/\/doi.org\/10.1111\/j.1468-3083.2011.04153.x; PMID:\u00a021689167.","DOI":"10.1111\/j.1468-3083.2011.04153.x"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature 2007;445:866\u201373. https:\/\/doi.org\/10.1038\/nature05663; PMID:\u00a017314973.","DOI":"10.1038\/nature05663"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Gelfand JM, Neimann AL, Shin DB, et al. Risk of myocardial infarction in patients with psoriasis. JAMA 2006;296:1735\u201341. https:\/\/doi.org\/10.1001\/jama.296.14.1735; PMID:\u00a017032986.","DOI":"10.1001\/jama.296.14.1735"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Ludwig RJ, Herzog C, Rostock A, et al. Psoriasis: a possible risk factor for development of coronary artery calcification. Br J Dermatol 2007;156:271\u20136. https:\/\/doi.org\/10.1111\/","DOI":"10.1111\/j.1365-2133.2006.07562.x"},{"key":"ref7","unstructured":"j.1365-2133.2006.07562.x; PMID:\u00a017223866."},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Parisi R, Rutter MK, Lunt M, et al. Psoriasis and the risk of major cardiovascular events: cohort study using the clinical practice research datalink. J Invest Dermatol 2015;135:2189\u201397. https:\/\/doi.org\/10.1038\/jid.2015.87; PMID:\u00a025742120.","DOI":"10.1038\/jid.2015.87"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Abuabara K, Azfar RS, Shin DB, et al. Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the UK. Br J Dermatol 2010;163:586\u201392. https:\/\/doi.org\/10.1111\/j.1365-2133.2010.09941.x; PMID:\u00a020633008.","DOI":"10.1111\/j.1365-2133.2010.09941.x"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Langan SM, Seminara NM, Shin DB, et al. Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom. J Invest Dermatol 2012;132:556\u201362. https:\/\/doi.org\/10.1038\/jid.2011.365; PMID:\u00a022113483.","DOI":"10.1038\/jid.2011.365"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Armstrong AW, Lin SW, Chambers CJ, et al. Psoriasis and hypertension severity: results from a case-control study. PLoS One 2011;6:e18227. https:\/\/doi.org\/10.1371\/journal.pone.0018227; PMID:\u00a021479272.","DOI":"10.1371\/journal.pone.0018227"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Caiazzo G, Fabbrocini G, Di Caprio R, et al. Psoriasis, cardiovascular events, and biologics: lights and shadows. Front Immunol 2018;9:1668. https:\/\/doi.org\/10.3389\/fimmu.2018.01668; PMID:\u00a030150978.","DOI":"10.3389\/fimmu.2018.01668"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Boehncke WH, Boehncke S, Tobin AM, et al. The \u2018psoriatic march\u2019: a concept of how severe psoriasis may drive cardiovascular comorbidity. Exp Dermatol 2011;20:303\u20137. https:\/\/doi.org\/10.1111\/j.1600-0625.2011.01261.x; PMID:\u00a021410760.","DOI":"10.1111\/j.1600-0625.2011.01261.x"},{"key":"ref14","unstructured":"Gottlieb A, Korman NJ, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol 2008;58:851\u201364. https:\/\/doi.org\/10.1016\/j.jaad.2008.02.040; PMID:\u00a018423261."},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Gisondi P, Bellinato F, Girolomoni G, et al. Pathogenesis of chronic plaque psoriasis and its intersection with cardio-metabolic comorbidities. Front Pharmacol 2020;11:117. https:\/\/doi.org\/10.3389\/fphar.2020.00117; PMID:\u00a032161545.","DOI":"10.3389\/fphar.2020.00117"},{"key":"ref16","unstructured":"Zeljko-Penavi\u0107 J, Situm M, Simi\u0107 D, Vurnek-Zivkovi\u0107 M. Quality of life in psoriatic patients and the relationship between type I and type II psoriasis. Coll Antropol 2010;34:195\u20138. PMID:\u00a020402318."},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Parisi R, Symmons DPM, Griffiths CEM, Ashcroft DM. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol 2013;133:377\u201385. https:\/\/doi.org\/10.1038\/jid.2012.339; PMID:\u00a023014338.","DOI":"10.1038\/jid.2012.339"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Kovitwanichkanont T, Chong AH, Foley P. Beyond skin deep: addressing comorbidities in psoriasis. Med J Aust 2020;212:528\u201334. https:\/\/doi.org\/10.5694\/mja2.50591; PMID:\u00a032388913.","DOI":"10.5694\/mja2.50591"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Vena GA, Vestita M, Cassano N. Psoriasis and cardiovascular disease. Dermatol Ther 2010;23:144\u201351. https:\/\/doi.org\/10.1111\/j.1529-8019.2010.01308.x; PMID:\u00a020415821.","DOI":"10.1111\/j.1529-8019.2010.01308.x"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Kaye JA, Li L, Jick SS. Incidence of risk factors for myocardial infarction and other vascular diseases in patients with psoriasis. Br J Dermatol 2008;159:895\u2013902. https:\/\/doi.org\/10.1111\/j.1365-2133.2008.08707.x; PMID:\u00a018616778.","DOI":"10.1111\/j.1365-2133.2008.08707.x"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Ahlehoff O, Gislason GH, Lindhardsen J, et al. Prognosis following first-time myocardial infarction in patients with psoriasis: a Danish nationwide cohort study. J Intern Med 2011;270:237\u201344. https:\/\/doi.org\/10.1111\/j.1365-2796.2011.02368.x; PMID:\u00a021362070.","DOI":"10.1111\/j.1365-2796.2011.02368.x"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Wang WM, Jin HZ. Homocysteine. Chin Med J (Engl) 2017;130:1980\u20136. https:\/\/doi.org\/10.4103\/0366-6999.211895; PMID:\u00a028776552.","DOI":"10.4103\/0366-6999.211895"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Israel L, Mellett M. Clinical and genetic heterogeneity of CARD14 mutations in psoriatic skin disease. Front Immunol 2018;9. https:\/\/doi.org\/10.3389\/fimmu.2018.02239; PMID:\u00a030386326.","DOI":"10.3389\/fimmu.2018.02239"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Harden JL, Lewis SM, Pierson KC, et al. CARD14 expression in dermal endothelial cells in psoriasis. PLoS One 2014;9:e111255. https:\/\/doi.org\/10.1371\/journal.pone.0111255;  PMID:\u00a025369198.","DOI":"10.1371\/journal.pone.0111255"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Sterry W, Strober BE, Menter A, et al. Obesity in psoriasis: the metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and review. Br J Dermatol 2007;157:649\u201355. https:\/\/doi.org\/10.1111\/j.1365-2133.2007.08068.x; PMID:\u00a017627791.","DOI":"10.1111\/j.1365-2133.2007.08068.x"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Choudhary S, Pradhan D, Pandey A, et al. The association of metabolic syndrome and psoriasis: A systematic review and meta-analysis of observational study. Endocr Metab Immune Disord Drug Targets 2020;20:703\u201317. https:\/\/doi.org\/10.2174\/1871530319666191008170409; PMID:\u00a031595859.","DOI":"10.2174\/1871530319666191008170409"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Mottillo S, Filion KB, Genest J, et al. The metabolic syndrome and cardiovascular risk: a systematic review and meta-analysis. J Am Coll Cardiol 2010;56:1113\u201332. https:\/\/doi.org\/10.1016\/j.jacc.2010.05.034; PMID:\u00a020863953.","DOI":"10.1016\/j.jacc.2010.05.034"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Owczarczyk-Saczonek A, Placek W. Compounds of psoriasis with obesity and overweight. Postepy Hig Med Dosw (Online) 2017;71:761\u201372. https:\/\/doi.org\/10.5604\/01.3001.0010.3854; PMID:\u00a028894050.","DOI":"10.5604\/01.3001.0010.3854"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"O\u2019Leary CJ, Creamer D, Higgins E, Weinman J. Perceived stress, stress attributions and psychological distress in psoriasis. J Psychosom Res 2004;57:465\u201371. https:\/\/doi.org\/10.1016\/j.jpsychores.2004.03.012; PMID:\u00a015581650.","DOI":"10.1016\/j.jpsychores.2004.03.012"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"Gerdes S, Zahl VA, Weichenthal M, Mrowietz U. Smoking and alcohol intake in severely affected patients with psoriasis in Germany. Dermatology 2010;220:38\u201343. https:\/\/doi.org\/10.1159\/000265557; PMID:\u00a019996578.","DOI":"10.1159\/000265557"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Fortes C, Mastroeni S, Leffondr\u00e9 K, et al. Relationship between smoking and the clinical severity of psoriasis. Arch Dermatol 2005;141:1580\u20134. https:\/\/doi.org\/10.1001\/archderm.141.12.1580; PMID:\u00a016365261.","DOI":"10.1001\/archderm.141.12.1580"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"Brenaut E, Horreau C, Pouplard C, et al. Alcohol consumption and psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol 2013;27:30\u20135. https:\/\/doi.org\/10.1111\/jdv.12164; PMID:\u00a023845150.","DOI":"10.1111\/jdv.12164"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"Adamzik K, McAleer MA, Kirby B. Alcohol and psoriasis: sobering thoughts. Clin Exp Dermatol 2013;38:819\u201322. https:\/\/doi.org\/10.1111\/ced.12013; PMID:\u00a024252076.","DOI":"10.1111\/ced.12013"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Prodanovich S, Prodanowich S, Ma F, et al. Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. J Am Acad Dermatol 2005;52:262\u20137. https:\/\/doi.org\/10.1016\/j.jaad.2004.06.017; PMID:\u00a015692471.","DOI":"10.1016\/j.jaad.2005.02.002"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"Sp\u00e4h F. Inflammation in atherosclerosis and psoriasis: common pathogenic mechanisms and the potential for an integrated treatment approach. Br J Dermatol 2008;159:10\u20137. https:\/\/doi.org\/10.1111\/j.1365-2133.2008.08780.x; PMID:\u00a018700910.","DOI":"10.1111\/j.1365-2133.2008.08780.x"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"Abou-Raya A, Abou-Raya S. Inflammation: a pivotal link between autoimmune diseases and atherosclerosis. Autoimmun Rev 2006;5:331\u20137. https:\/\/doi.org\/10.1016\/j.autrev.2005.12.006; PMID:\u00a016782558.","DOI":"10.1016\/j.autrev.2005.12.006"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"Hahn BH, Grossman J, Chen W, McMahon M. The pathogenesis of atherosclerosis in autoimmune rheumatic diseases: roles of inflammation and dyslipidemia. J Autoimmun 2007;28:69\u201375. https:\/\/doi.org\/10.1016\/j.jaut.2007.02.004; PMID:\u00a017433865.","DOI":"10.1016\/j.jaut.2007.02.004"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008;371:1665\u201374. https:\/\/doi.org\/10.1016\/S0140-6736(08)60725-4; PMID:\u00a018486739.","DOI":"10.1016\/s0140-6736(08)60725-4"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"Res PCM, Piskin G, de Boer OJ, et al. Overrepresentation of IL-17A and IL-22 producing CD8 T cells in lesional skin suggests their involvement in the pathogenesis of psoriasis. PLoS One 2010;5:e14108. https:\/\/doi.org\/10.1371\/journal.pone.0014108; PMID:\u00a021124836.","DOI":"10.1371\/journal.pone.0014108"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"Alexandroff AB, Pauriah M, Camp RDR, et al. More than skin deep: atherosclerosis as a systemic manifestation of psoriasis. Br J Dermatol 2009;161:1\u20137. https:\/\/doi.org\/10.1111\/j.1365-2133.2009.09281.x; PMID:\u00a019500102.","DOI":"10.1111\/j.1365-2133.2009.09281.x"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"Ahlehoff O, Gislason GH, Charlot M, et al. Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study. J Intern Med 2011;270:147\u201357. https:\/\/doi.org\/10.1111\/j.1365-2796.2010.02310.x; PMID:\u00a021114692.","DOI":"10.1111\/j.1365-2796.2010.02310.x"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"Sorokin AV, Kotani K, Elnabawi YA, et al. Association between oxidation-modified lipoproteins and coronary plaque in psoriasis. Circ Res 2018;123:1244\u201354. https:\/\/doi.org\/10.1161\/CIRCRESAHA.118.313608; PMID:\u00a030571459.","DOI":"10.1161\/circresaha.118.313608"},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"Jialal I, Remaley AT. Measurement of low-density lipoprotein cholesterol in assessment and management of cardiovascular disease risk. Clin Pharmacol Ther 2014;96:20\u20132. https:\/\/doi.org\/10.1038\/clpt.2014.69; PMID:\u00a024942398.","DOI":"10.1038\/clpt.2014.69"},{"key":"ref44","doi-asserted-by":"publisher","unstructured":"Chen C, Khismatullin DB. Oxidized low-density lipoprotein contributes to atherogenesis via co-activation of macrophages and mast cells. PLoS One 2015;10:e0123088. https:\/\/doi.org\/10.1371\/journal.pone.0123088; PMID:\u00a025811595.","DOI":"10.1371\/journal.pone.0123088"},{"key":"ref45","doi-asserted-by":"publisher","unstructured":"Veglia F, Perego M, Gabrilovich D. Myeloid-derived suppressor cells coming of age. Nat Immunol 2018;19:108\u201319. https:\/\/doi.org\/10.1038\/s41590-017-0022-x; PMID:\u00a029348500.","DOI":"10.1038\/s41590-017-0022-x"},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"Chen C, Tan L, Zhu W, et al. Targeting myeloid-derived suppressor cells is a novel strategy for anti-psoriasis therapy. Mediators Inflamm 2020;2020:8567320. https:\/\/doi.org\/10.1155\/2020\/8567320; PMID:\u00a032684837.","DOI":"10.1155\/2020\/8567320"},{"key":"ref47","doi-asserted-by":"publisher","unstructured":"Lowes MA, Su\u00e1rez-Fari\u00f1as M, Krueger JG. Immunology of psoriasis. Annu Rev Immunol 2014;32:227\u201355. https:\/\/doi.org\/10.1146\/annurev-immunol-032713-120225; PMID:\u00a024655295.","DOI":"10.1146\/annurev-immunol-032713-120225"},{"key":"ref48","doi-asserted-by":"publisher","unstructured":"Fan Z, Wang L, Jiang H, et al. Platelet dysfunction and its role in the pathogenesis of psoriasis. Dermatology 2021;237:56\u201365. https:\/\/doi.org\/10.1159\/000505536; PMID:\u00a032349003.","DOI":"10.1159\/000505536"},{"key":"ref49","doi-asserted-by":"publisher","unstructured":"Liu X, Gorzelanny C, Schneider SW. Platelets in skin autoimmune diseases. Front Immunol 2019;10:1453. https:\/\/doi.org\/10.3389\/fimmu.2019.01453; PMID:\u00a031333641.","DOI":"10.3389\/fimmu.2019.01453"},{"key":"ref50","doi-asserted-by":"publisher","unstructured":"Thorslund K, El-Nour H, Nordlind K. The serotonin transporter protein is expressed in psoriasis, where it may play a role in regulating apoptosis. Arch Dermatol Res 2009;301:449\u201357. https:\/\/doi.org\/10.1007\/s00403-009-0933-y; PMID:\u00a019263059.","DOI":"10.1007\/s00403-009-0933-y"},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"51.Ketelhuth DFJ, Lutgens E, B\u00e4ck M, et al. Immunometabolism and atherosclerosis: perspectives and clinical significance: a position paper from the Working Group on Atherosclerosis and Vascular Biology of the European Society of Cardiology. Cardiovasc Res 2019;115:1385\u201392. https:\/\/doi.org\/10.1093\/cvr\/cvz166; PMID:\u00a031228191.","DOI":"10.1093\/cvr\/cvz166"},{"key":"ref52","doi-asserted-by":"publisher","unstructured":"Piaserico S, Osto E, Famoso G, et al. Long-term prognostic value of coronary flow reserve in psoriasis patients. Atherosclerosis 2019;289:57\u201363. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2019.08.009; PMID:\u00a031476732.","DOI":"10.1016\/j.atherosclerosis.2019.08.009"},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"Weber B, Perez-Chada LM, Divakaran S, et al. Coronary microvascular dysfunction in patients with psoriasis. J Nucl Cardiol 2020. https:\/\/doi.org\/10.1007\/s12350-020-02166-5; PMID:\u00a032419071; epub ahead of press.","DOI":"10.1007\/s12350-020-02166-5"},{"key":"ref54","doi-asserted-by":"publisher","unstructured":"Taqueti VR, Di Carli MF. Coronary microvascular disease pathogenic mechanisms and therapeutic options: JACC state-of-the-art review. J Am Coll Cardiol 2018;72:2625\u201341. https:\/\/doi.org\/10.1016\/j.jacc.2018.09.042; PMID:\u00a030466521.","DOI":"10.1016\/j.jacc.2018.09.042"},{"key":"ref55","doi-asserted-by":"crossref","unstructured":"Ong P, Camici PG, Beltrame JF, et al. International standardization of diagnostic criteria for microvascular angina. Int J Cardiol 2018;250:16\u201320. https:\/\/doi.org\/10.1016\/j.ijcard.2017.08.068; PMID:\u00a029031990.","DOI":"10.1016\/j.ijcard.2017.08.068"},{"key":"ref56","doi-asserted-by":"publisher","unstructured":"Osto E, Piaserico S, Maddalozzo A, et al. Impaired coronary flow reserve in young patients affected by severe psoriasis. Atherosclerosis 2012;221:113\u20137. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2011.12.015; PMID:\u00a022236480.","DOI":"10.1016\/j.atherosclerosis.2011.12.015"},{"key":"ref57","doi-asserted-by":"publisher","unstructured":"Alba BK, Greaney JL, Ferguson SB, et al. Endothelial function is impaired in the cutaneous microcirculation of adults with psoriasis through reductions in nitric oxide-dependent vasodilation. Am J Physiol Circ Physiol 2018;314:h343\u20139. https:\/\/doi.org\/10.1152\/ajpheart.","DOI":"10.1152\/ajpheart.00446.2017"},{"key":"ref58","unstructured":"00446.2017; PMID:\u00a029054972."},{"key":"ref59","doi-asserted-by":"publisher","unstructured":"Sunbul M, Seckin D, Durmus E, et al. Assessment of arterial stiffness and cardiovascular hemodynamics by oscillometric method in psoriasis patients with normal cardiac functions. Heart Vessels 2015;30:347\u201354. https:\/\/doi.org\/10.1007\/s00380-014-0490-y; PMID:\u00a024633494.","DOI":"10.1007\/s00380-014-0490-y"},{"key":"ref60","doi-asserted-by":"publisher","unstructured":"Kagami S, Rizzo HL, Lee JJ, et al. Circulating Th17, Th22, and Th1 cells are increased in psoriasis. J Invest Dermatol 2010;130:1373\u201383. https:\/\/doi.org\/10.1038\/jid.2009.399; PMID:\u00a020032993.","DOI":"10.1038\/jid.2009.399"},{"key":"ref61","doi-asserted-by":"publisher","unstructured":"P\u00e8ne J, Chevalier S, Preisser L, et al. Chronically inflamed human tissues are infiltrated by highly differentiated Th17 lymphocytes. J Immunol 2008;180:7423\u201330. https:\/\/doi.org\/10.4049\/jimmunol.180.11.7423; PMID:\u00a018490742.","DOI":"10.4049\/jimmunol.180.11.7423"},{"key":"ref62","doi-asserted-by":"publisher","unstructured":"Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005;352:1685\u201395. https:\/\/doi.org\/10.1056\/NEJMra043430; PMID:\u00a015843671.","DOI":"10.1056\/nejmra043430"},{"key":"ref63","doi-asserted-by":"publisher","unstructured":"Ormerod AD, Copeland P, Shah SA. Treatment of psoriasis with topical NG-monomethyl-L-arginine, an inhibitor of nitric oxide synthesis. Br J Dermatol 2000;142:985\u201390. https:\/\/doi.org\/10.1046\/j.1365-2133.2000.03483.x; PMID:\u00a010809860.","DOI":"10.1046\/j.1365-2133.2000.03483.x"},{"key":"ref64","doi-asserted-by":"publisher","unstructured":"Sirsj\u00f6 A, Karlsson M, Gidl\u00f6f A, et al. Increased expression of inducible nitric oxide synthase in psoriatic skin and cytokine-stimulated cultured keratinocytes. Br J Dermatol 1996;134:643\u20138. https:\/\/doi.org\/10.1111\/j.1365-2133.1996.tb06963.x; PMID:\u00a08733364.","DOI":"10.1111\/j.1365-2133.1996.tb06963.x"},{"key":"ref65","doi-asserted-by":"crossref","unstructured":"Naseem K. The role of nitric oxide in cardiovascular diseases. Mol Aspects Med 2005;26:33\u201365. https:\/\/doi.org\/10.1016\/j.mam.2004.09.003; PMID:\u00a015722114.","DOI":"10.1016\/j.mam.2004.09.003"},{"key":"ref66","unstructured":"Gupta M, Chari S, Borkar M, et al. Dyslipidemia and oxidative stress in patients of psoriasis. Biomedical Research 2011;22."},{"key":"ref67","doi-asserted-by":"publisher","unstructured":"Rocha-Pereira P, Santos-Silva A, Rebelo I, et al. Dislipidemia and oxidative stress in mild and in severe psoriasis as a risk for cardiovascular disease. Clin Chim Acta 2001;303:33\u20139. https:\/\/doi.org\/10.1016\/s0009-8981(00)00358-2; PMID:\u00a011163020.","DOI":"10.1016\/s0009-8981(00)00358-2"},{"key":"ref68","doi-asserted-by":"publisher","unstructured":"Salihbegovic EM, Hadzigrahic N, Suljagic E, et al. Psoriasis and high blood pressure. Med Arch 2015;69:13\u20135. https:\/\/doi.org\/10.5455\/medarh.2015.69.13-15; PMID:\u00a025870469.","DOI":"10.5455\/medarh.2015.69.13-15"},{"key":"ref69","doi-asserted-by":"publisher","unstructured":"Ito T, Furukawa F, Iwatsuki K, et al. Efficacious treatment of psoriasis with low-dose and intermittent cyclosporin microemulsion therapy. J Dermatol 2014;41:377\u201381. https:\/\/doi.org\/10.1111\/1346-8138.12455; PMID:\u00a024628433.","DOI":"10.1111\/1346-8138.12455"},{"key":"ref70","doi-asserted-by":"publisher","unstructured":"Hoorn EJ, Walsh SB, McCormick JA, et al. Pathogenesis of calcineurin inhibitor-induced hypertension. J Nephrol 2012;25:269\u201375. https:\/\/doi.org\/10.5301\/jn.5000174; PMID:\u00a022573529.","DOI":"10.5301\/jn.5000174"},{"key":"ref71","doi-asserted-by":"publisher","unstructured":"Ryan C, Kirby B. Psoriasis is a systemic disease with multiple cardiovascular and metabolic comorbidities. Dermatol Clin 2015;33:41\u201355. https:\/\/doi.org\/10.1016\/j.det.2014.09.004; PMID:\u00a025412782.","DOI":"10.1016\/j.det.2014.09.004"},{"key":"ref72","doi-asserted-by":"publisher","unstructured":"Lifton RP, Gharavi AG, Geller DS. Molecular mechanisms of human hypertension. Cell 2001;104:545\u201356. https:\/\/doi.org\/10.1016\/s0092-8674(01)00241-0; PMID:\u00a011239411.","DOI":"10.1016\/s0092-8674(01)00241-0"},{"key":"ref73","doi-asserted-by":"crossref","unstructured":"Foy MC, Vaishnav J, Sperati CJ. Drug-induced hypertension. Endocrinol Metab Clin North Am 2019;48:859\u201373. https:\/\/doi.org\/10.1016\/j.ecl.2019.08.013; PMID:\u00a031655781.","DOI":"10.1016\/j.ecl.2019.08.013"},{"key":"ref74","doi-asserted-by":"publisher","unstructured":"Ortiz NEG, Nijhawan RI, Weinberg JM. Acitretin. Dermatol Ther 2013;26:390\u20139. https:\/\/doi.org\/10.1111\/dth.12086; PMID:\u00a024099069.","DOI":"10.1111\/dth.12086"},{"key":"ref75","doi-asserted-by":"crossref","unstructured":"Ridker PM, Everett BM, Pradhan A, et al. Low-dose methotrexate for the prevention of atherosclerotic events. N Engl J Med 2019;380:752\u201362. https:\/\/doi.org\/10.1056\/NEJMoa1809798; PMID:\u00a030415610.","DOI":"10.1056\/NEJMoa1809798"},{"key":"ref76","doi-asserted-by":"publisher","unstructured":"Ryan C, Leonardi CL, Krueger JG, et al. Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. JAMA 2011;306:864\u201371. https:\/\/doi.org\/10.1001\/jama.2011.1211; PMID:\u00a021862748.","DOI":"10.1001\/jama.2011.1211"},{"key":"ref77","doi-asserted-by":"publisher","unstructured":"Rungapiromnan W, Yiu ZZN, Warren RB, et al. Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta-analysis of randomized controlled trials. Br J Dermatol 2017;176:890\u2013901. https:\/\/doi.org\/10.1111\/bjd.14964; PMID:\u00a027518205.","DOI":"10.1111\/bjd.14964"},{"key":"ref78","doi-asserted-by":"crossref","unstructured":"Elmets CA, Leonardi CL, Davis DMR, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. J Am Acad Dermatol 2019;80:1073\u2013113. https:\/\/doi.org\/10.1016\/j.jaad.2018.11.058; PMID:\u00a030772097.","DOI":"10.1016\/j.jaad.2018.11.058"},{"key":"ref79","doi-asserted-by":"crossref","unstructured":"Mehta NN, Shin DB, Joshi AA, et al. Effect of 2 psoriasis treatments on vascular inflammation and novel inflammatory cardiovascular biomarkers: a randomized placebo-controlled trial. Circ Cardiovasc Imaging 2018;11:e007394. https:\/\/doi.org\/10.1161\/CIRCIMAGING.117.007394; PMID:\u00a029776990.","DOI":"10.1161\/CIRCIMAGING.117.007394"},{"key":"ref80","doi-asserted-by":"publisher","unstructured":"Gelfand JM, Shin DB, Alavi A, et al. A Phase IV, randomized, double-blind, placebo-controlled crossover study of the effects of ustekinumab on vascular inflammation in psoriasis (the VIP-U trial). J Invest Dermatol 2020;140:85\u201393.e2. https:\/\/doi.org\/10.1016\/j.jid.2019.07.679; PMID:\u00a031326395.","DOI":"10.1016\/j.jid.2019.07.679"},{"key":"ref81","doi-asserted-by":"publisher","unstructured":"Yang Z, Lin N, Li L, Li Y. The effect of TNF inhibitors on cardiovascular events in psoriasis and psoriatic arthritis: an updated meta-analysis. Clin Rev Allergy Immunol 2016;51:240\u20137. https:\/\/doi.org\/10.1007\/s12016-016-8560-9; PMID:\u00a027300248.","DOI":"10.1007\/s12016-016-8560-9"},{"key":"ref82","doi-asserted-by":"publisher","unstructured":"Marti CN, Khan H, Mann DL, et al. Soluble tumor necrosis factor receptors and heart failure risk in older adults: Health, Aging, and Body Composition (Health ABC) Study. Circ Heart Fail 2014;7:5\u201311. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.113.000344; PMID:\u00a024323631.","DOI":"10.1161\/circheartfailure.113.000344"},{"key":"ref83","doi-asserted-by":"publisher","unstructured":"Balato A, Schiattarella M, Di Caprio R, et al. Effects of adalimumab therapy in adult subjects with moderate-to-severe psoriasis on Th17 pathway. J Eur Acad Dermatol Venereol 2014;28:1016\u201324. https:\/\/doi.org\/10.1111\/jdv.12240; PMID:\u00a024033358.","DOI":"10.1111\/jdv.12240"},{"key":"ref84","doi-asserted-by":"publisher","unstructured":"Boehncke S, Salgo R, Garbaraviciene J, et al. Effective continuous systemic therapy of severe plaque-type psoriasis is accompanied by amelioration of biomarkers of cardiovascular risk: results of a prospective longitudinal observational study. J Eur Acad Dermatol Venereol 2011;25:1187\u201393. https:\/\/doi.org\/10.1111\/j.1468-3083.","DOI":"10.1111\/j.1468-3083.2010.03947.x"},{"key":"ref85","unstructured":"2010.03947.x; PMID:\u00a021241371."},{"key":"ref86","doi-asserted-by":"publisher","unstructured":"Marra M, Campanati A, Testa R, et al. Effect of etanercept on insulin sensitivity in nine patients with psoriasis. Int J Immunopathol Pharmacol 2007;20:731\u20136. https:\/\/doi.org\/10.1177\/039463200702000408; PMID:\u00a018179745.","DOI":"10.1177\/039463200702000408"},{"key":"ref87","doi-asserted-by":"publisher","unstructured":"Pina T, Armesto S, Lopez-Mejias R, et al. Anti-TNF-\u03b1 therapy improves insulin sensitivity in non-diabetic patients with psoriasis: a 6-month prospective study. J Eur Acad Dermatol Venereol 2015;29:1325\u201330. https:\/\/doi.org\/10.1111\/jdv.12814; PMID:\u00a025353352.","DOI":"10.1111\/jdv.12814"},{"key":"ref88","doi-asserted-by":"publisher","unstructured":"Pina T, Genre F, Lopez-Mejias R, et al. Anti-TNF-\u03b1 therapy reduces retinol-binding protein 4 serum levels in non-diabetic patients with psoriasis: a 6-month prospective study. J Eur Acad Dermatol Venereol 2016;30:92\u20135. https:\/\/doi.org\/10.1111\/jdv.13005; PMID:\u00a025650695.","DOI":"10.1111\/jdv.13005"},{"key":"ref89","doi-asserted-by":"publisher","unstructured":"Ahlehoff O, Hansen PR, Gislason GH, et al. Myocardial function and effects of biologic therapy in patients with severe psoriasis: a prospective echocardiographic study. J Eur Acad Dermatol Venereol 2016;30:819\u201323. https:\/\/doi.org\/10.1111\/jdv.13152; PMID:\u00a025845841.","DOI":"10.1111\/jdv.13152"},{"key":"ref90","doi-asserted-by":"publisher","unstructured":"Her\u00e9di E, V\u00e9gh J, Pog\u00e1cs\u00e1s L, et al. Subclinical cardiovascular disease and it\u2019s improvement after long-term TNF-\u03b1 inhibitor therapy in severe psoriatic patients. J Eur Acad Dermatol Venereol 2016;30:1531\u20136. https:\/\/doi.org\/10.1111\/jdv.13649; PMID:\u00a027393182.","DOI":"10.1111\/jdv.13649"},{"key":"ref91","doi-asserted-by":"publisher","unstructured":"Mann DL, McMurray JJV, Packer M, et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 2004;109:1594\u2013602. https:\/\/doi.org\/10.1161\/01.CIR.0000124490.27666.B2; PMID:\u00a015023878.","DOI":"10.1161\/01.cir.0000124490.27666.b2"}],"container-title":["European Cardiology Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ecrjournal.com\/articleindex\/ecr.2020.15.R2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T12:46:38Z","timestamp":1620996398000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ecrjournal.com\/articleindex\/ecr.2020.15.R2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,13]]},"references-count":92,"URL":"https:\/\/doi.org\/10.15420\/ecr.2020.15.r2","relation":{},"ISSN":["1758-3764","1758-3756"],"issn-type":[{"value":"1758-3764","type":"electronic"},{"value":"1758-3756","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5,13]]},"article-number":"e19"}}